FDA (CDER)
GUIDANCE DRAFT
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4): Draft Guidance for Industry
Published: 3/9/2026Detected: 3/20/2026
Summary preview
Clarifies FDA expectations for how sponsors should develop biosimilar candidates under the BPCI Act, including the types of evidence and questions FDA will focus on during review.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#biosimilar development
#BPCI Act
#draft guidance
#FDA CDER
#Q&A
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026